Clinical trial
COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect…
NCT00497328 · National University Hospital, Singapore, Other · Completed
Key facts
| NCT number | NCT00497328 |
|---|---|
| Title | COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT |
| Official title | An Open Labelled Randomized Multi-center Study of COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Incidence of Contrast Induced Nephropathy |
| Acronym | CONTRAST |
| Lead sponsor | National University Hospital, Singapore, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Contrast Induced Nephropathy |
| Intervention type | Drug |
| Interventions | N-acetylcysteine, Sodium Bicarbonate |
| Enrollment | 477 |
| Start date | Aug 1, 2007 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Jul 6, 2007 |
| Last update posted | Jan 14, 2014 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: